500 patients enrolled in Largest-Ever study of brain tapeworm outcomes
NCT ID NCT00001205
First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 7 times
Summary
This study follows 500 people with neurocysticercosis, a brain infection caused by the pork tapeworm. Participants receive standard antiparasitic drugs and anti-inflammatories. Researchers will track their health over many years to understand what factors lead to better or worse outcomes. The goal is to improve future treatment and reduce complications like seizures and stroke.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- praziquantel and/or albendazole (antiparasitic drugs) plus anti-inflammatory medications
- What this could lead to
- If successful, this could help doctors better predict and manage long-term complications of neurocysticercosis, leading to improved treatment guidelines.
- What could go wrong
- This is an observational study, not a test of a new treatment. It will not directly produce a cure or new drug, and results may take years to influence practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTICERCOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.